That’s why two people with the same kind of cancer can react very differently to the same medicine.
In one the tumour gets smaller, in another the degenerated tissue remains unaffected. Usually this is due to genetic variations in the individual cancer cells.
In order to understand these variations in detail and better adapt therapies to the individual needs of patients in the future, an international team of more than 1,500 scientists – the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium – decided several years ago to trace the common mutation patterns in the genomes of about 3,000 cancer patients.
The donated tissue samples included tumours of the liver, pancreas, brain, and 17 other organs.
PCAWG researchers used data from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) for their project.
Participants in those groups had already completely sequenced the genomes and transcriptomes, that is the entire set of RNA molecules, of 1,188 degenerated tissue samples.
Regulatory sequences of DNA were also decoded
“Thanks to PCAWG, not only have the parts of genomes containing the blueprints for proteins from such a large number of patient samples been studied for the first time, but so have the regulatory sequences of DNA that control the expression of genes,” said Dr Roland Schwarz, head of the Evolutionary and Cancer Genomics Group at the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association.
Schwarz is one of seven senior authors of the study which has been published in Nature.
This publication is the main paper of PCAWG Working Group 3 “Integration of Transcriptome and Genome.” Two scientists from Schwarz’s own research group at the Berlin Institute for Medical Systems Biology (BIMSB) at the MDC – Dr. Matthew Robert Huska and Julia Markowski – also contributed to the paper.
“In our work, we and our colleagues systematically studied a variety of RNA alterations and identified mutations on the DNA level that cause these RNA alterations,” Schwarz explained.
Cancer-specific alterations on the RNA level have long been known.
“Genes often get overexpressed in tumours, causing the formation of more RNA,” said Schwarz. “Or there are gene fusions or modifications in splicing, an important step in the formation of RNA.”
Structural alterations in the genome play a decisive role
Until now, however, it has been rather unclear which DNA mutations are caused by the known RNA alterations.
The work done by Schwarz and 49 other researchers has filled a significant gap in geneticists’ understanding of carcinogenesis.
“An especially important focus of our work at the MDC has been on the interplay between selective DNA mutations and structural alterations, such as gene copy number variants,” Schwarz reported. “Our cells normally contain two inherited copies of each and every chromosome, a maternal and a paternal allele.” In cancer cells, the number of copies is often much higher, or entire segments of the genome have gone missing.”
Using high-performance computers and cloud computing, Schwarz and his team have found out that such alterations in copy number play a decisive role in the altered gene expression of cancer cells.
“By analysing the DNA sequences of the entire genome, we have been able to accurately determine how copy number variants work together with point mutations – and what influence this in turn has on the expression of a specific parental allele,” Schwarz explained.
Every one of a cell’s three billion base pairs can mutate
Schwarz hopes that the work he and his colleagues are doing will significantly improve our understanding of gene regulation in tumours.
“Our study will certainly lay the foundation for further research that will help us to become more familiar with the genetic heterogeneity of tumours,” he said.
For the fact is that every single one of the approximately three billion base pairs contained in a human genome could theoretically mutate.
“To find out how cells actually degenerate, we have to distinguish between significant and insignificant mutations,” Schwarz said.
And that’s only possible with a large number of tumour samples along with a large number of dedicated researchers, such as we see united in the PCAWG consortium.
The main paper the group plans to publish will certainly be of major interest.